- Original article
- Open Access
Allergic Rhinitis and its Impact on Asthma scores in asthmatic patients with and without allergic rhinitis
The Egyptian Journal of Otolaryngology volume 30, pages112–121(2014)
Allergic rhinitis and allergic asthma are chronic inflammatory conditions that frequently coexist, both with hallmark eosinophilia. Immunotherapy is an established treatment for allergic diseases. Noninjective routes for immunotherapy, such as the sublingual route, are thought to be valuable therapeutic options for respiratory allergy.
Aim of the study
In the present study, sublingual immunotherapy (SLIT) using multiple allergens was administered to allergic asthmatic patients with and without allergic rhinitis aiming to evaluate the clinical efficacy of and changes in allergen-specific antibodies during SLIT and its effect on control of asthma severity and nasal allergy scores.
Patients and methods
The study included 40 patients in two groups: group I included 20 asthmatic patients and group II included 20 patients with both proven bronchial asthma and allergic rhinitis. All patients were subjected to assessment of the status of asthma and hence its degree of control using the Global Initiative for Asthma (GINA) guidelines; patients received SLIT according to the results over a period of 1 year and were clinically reassessed monthly. In addition, for the recruited candidates, the initial total immunoglobulin E (IgE) levels were measured and pulmonary function tests were performed at the time of recruitment and repeated after 6 months and 1 year of the initiation of the course of SLIT. SLIT was stopped for asthmatic patients during acute exacerbation and resumed after complete asthma control.
There was a statistically significant decrease in blood eosinophils but a statistically insignificant decrease in total IgE 1 year after SLIT in both groups. Results of specific IgE to food and inhalants revealed that there was statistically significant reduction in the number of allergens in both groups 1 year after SLIT. Results of the skin prick test revealed similar results. Our results revealed that the scores of, both Allergic Rhinitis and its Impact on Asthma and GINA had improved in all patients after 1 year of continuous therapy.
SLIT is a safe treatment strategy that significantly reduces symptoms and medication requirements and improves asthma control in both asthmatic patients with and without allergic rhinitis. SLIT using multiple allergens lowered the allergen burden in both asthmatic patients with and those without allergic rhinitis.
Level of evidence
1b (Clinical Decision Rule tested within one clinical center).
GINA Science Committee. Global Strategy for Asthma Management and Prevention 2009. Available at: http://www.ginasthma.com. [Last accessed on 2013 10 Jan]
Waibel V, Ulmer H, Horak E. Assessing asthma control: symptom scores, GINA levels of asthma control, lung function, and exhaled nitric oxide. Pediatr Pulmonol 2012; 47: 113–118.
Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4–12.
Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147–S334.
Rimmer J, Ruhno JW. Rhinitis and asthma: united airway disease. Med J Aust 2006; 185: 565–571.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63:8–160.
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, Zuberbier T. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009; 124: 428–433.
Cox LS. Sublingual immunotherapy, part 1: review of clinical efficacy — will this soon be an option for some of your patients? J Respir Dis 2007; 28: 162–168.
Ortolani C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M, et al. Practice parameters for sublingual immunotherapy. Monaldi Arch Chest Dis 2006; 65: 44–46.
Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009; 124:665–670.
Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 12:CD002893.
Montoro J, Del Cuvillo A, Mullol J, Molina X, Bartra J, Dávila I, et al. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study. Allergy 2012; 67:1437–1442.
Crimi E, Milanese M, Oddera S, Mereu C, Rossi GA, Riccio A, et al. Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis. J Appl Physiol 2001; 91:1029–1034.
Halpern MT, Schmier JK, Richner R, Guo C, Togias A. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma 2004; 41:117–126.
Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90:250–256.
Wood RA, Eggleston PA. The effects of intranasal steroids on nasal and pulmonary responses to cat exposure. Am J Respir Crit Care Med 1995; 151:315–320.
Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:57–62.
Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119:881–891.
Mohapatra SS, Qazi M, Hellermann G Immunotherapy for allergies and asthma: present and future. Curr Opin Pharmacol 2010; 10:276–288.
Nelson HS Allergen immunotherapy: where is it now? J Allergy Clin Immunol 2007; 119:769–777.
Senti G, Freiburghaus AU, Kundig TM Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Curr Opin Allergy Clin Immunol 2010; 10:582–586.
Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252–3259.
Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761–771.
Passalacqua G, Lombardi C, Canonica GW. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol 2004; 4:31–36.
Kim S-T, Han DH, Moon IJ, Lee CH, Min Y-G, Rhee C-S. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy 2010; 24:271–275.
La Grutta S, Arena A, D’Anneo W-R, Gammeri E, Leonardi S, Trimarchi A, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial. Eur Ann Allergy Clin Immunol 2007; 39:40–44.
Abd Elwadowd MR, Salem KA. Sublingual immunotherpay as a relevant alterative in treatment of allergic rhinitis, an intervention study. Egypt J Med Lab Sci, (ESIC) 2005; 14:31–38.
Al-Shehri A. Specific sublingual immunotherapy. Internet J Asthma Allergy Immunol 2001; 2:72–74.
Wise SK, Woody J, Koepp S, Schlosser RJ. Quality of life outcomes with sublingual immunotherapy. Am J Otolaryngol 2009; 30:305–311.
Tripathi DM, Joshi SV, Dhar HL. Efficacy of sublingual immunotherapy with multiple allergens in bronchial asthma. Bombay Hosp J 2008; 50:227–231.
Bahceciler NN, Arikan C, Taylor A, Akdis M, Blaser K, Barlan IB, Akdis CA. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287–294.
Pajno GB, Vita D, Caminiti L, Arrigo T, Lombardo F, Incorvaia C, Barberio G. Children’s compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005; 116:1380–1381.
Steiner L, Engel T, Nöding A, Licht M, Delaney A, Distler A, et al. Description of long term outcome of sublingual immunotherapy treatment in children: a follow-up observation through phone interviews. Open Allergy J 2009; 2:30–37.
Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:565–571.
Abramson MJ, Puy RM, Weiner JM Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000; 2:CD001186.
Lue K-H, Lin Y-H, Sun H-L, Lu K-H, Hsieh J-C, Chou M-C Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408–415.
Bahçeciler NN, Iºik U, Barlan IB, Baºaran MM Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32:49–55.
Ferrés J, Justicia J-L, García MP, Muñoz-Tudurí M, Alvà V. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr) 2011; 39:122–127.
Conflicts of interest
There are no conflicts of interest.
About this article
Cite this article
Taha, M.S., Youssef, T., Abd-Alsamee, H.F. et al. Allergic Rhinitis and its Impact on Asthma scores in asthmatic patients with and without allergic rhinitis. Egypt J Otolaryngol 30, 112–121 (2014). https://doi.org/10.4103/1012-5574.133210
- allergic rhinitis
- bronchial asthma
- multiple allergens
- sublingual immunotherapy